- Trade Name: Synribo (Ivax)
- Indications: Chronic myeloid leukemia (CML) in patients with resistance and/or intolerance to two or more tyrosine kinase inhibitors
- Class: Protein synthesis inhibitor
- Half-life: ~6 hours
- Clinically important, potentially hazardous interactions with:
None known
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of omacetaxine in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 08/20/2025
